医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Verdezyne Formalizes $48 Million Financing at Signing Ceremony Attended by President Barack Obama

2014年04月29日 AM07:30
このエントリーをはてなブックマークに追加

Smart Multimedia Gallery

 

President Barack Obama, standing right, and Malaysian Prime Minister Najib Razak, standing left, applaud as Bill Radany, president & CEO of Verdezyne, right, and Tan Sri Dato' Seri Mohd Bakke Salleh, President & Group Chief Executive of Sime Darby Berthed, left, participate in the signing of major commercial agreements with American businesses at the Ritz-Carlton in Kuala Lumpur, Malaysia, Monday, April 28, 2014. (AP Photo/Carolyn Kaster)President Barack Obama, standing right, and Malaysian Prime Minister Najib Razak, standing left, applaud as Bill Radany, president & CEO of Verdezyne, right, and Tan Sri Dato’ Seri Mohd Bakke Salleh, President & Group Chief Executive of Sime Darby Berthed, left, participate in the signing of major commercial agreements with American businesses at the Ritz-Carlton in Kuala Lumpur, Malaysia, Monday, April 28, 2014. (AP Photo/Carolyn Kaster)

View and Share Photo

Close Window


CARLSBAD, Calif. & KUALA LUMPUR, Malaysia

Verdezyne, Inc., a privately held industrial biotechnology company focused on producing renewable chemicals, has negotiated key terms for an investment of $48 million led by Malaysian multinational conglomerate, Sime Darby Berhad. The initiative was launched in a ceremony on Monday, April 28, at the Ritz-Carlton in Kuala Lumpur, Malaysia, attended by United States President Barack Obama, Malaysian Prime Minister Dato’ Sri Najib Razak, Verdezyne President and CEO E. William Radany, Ph.D., and Sime Darby Berhad President and Group Chief Executive, Tan Sri Dato’ Seri Mohd Bakke Salleh.

President Barack Obama, standing right, and Malaysian Prime Minister Najib Razak, standing left, app ...

President Barack Obama, standing right, and Malaysian Prime Minister Najib Razak, standing left, applaud as Bill Radany, president & CEO of Verdezyne, right, and Tan Sri Dato’ Seri Mohd Bakke Salleh, President & Group Chief Executive of Sime Darby Berthed, left, participate in the signing of major commercial agreements with American businesses at the Ritz-Carlton in Kuala Lumpur, Malaysia, Monday, April 28, 2014. (AP Photo/Carolyn Kaster)

“It is an honor and a true privilege that both President Barack Obama and Prime Minister Najib Razak chose to attend our signing ceremony today,” commented Dr. Radany. “It speaks to the significance of this agreement for the renewable chemicals space and to strengthening ties between the U.S. and Malaysia. Moreover, it highlights the important environmental and geo-political benefits of replacing petroleum-derived materials with renewable sources. We hope that this agreement, and the technology development it will enable, can serve as a model for how the U.S. can lead the world in the development of environmentally-friendly products. Over the past year, with the invaluable assistance of the Malaysian Biotechnology Corporation, Verdezyne’s management team researched the oil palm industry extensively. We believe that Sime Darby, with its commitment to sustainability, is the perfect partner to help lead the revolution in renewable products in the U.S., Malaysia and beyond.”

The funds will be used to accelerate Verdezyne’s technology development in the U.S., and support various collaborative projects with Sime Darby’s newly-formed business unit, Sime Darby Renewables. Led by Sime Darby, this $48 million financing for Verdezyne was joined by existing investors BP Alternative Energy Ventures, DSM Venturing B.V., OVP Venture Partners, and Monitor Ventures.

“We could not be more pleased to be entering into this relationship with Verdezyne, and are truly honored that U.S. President Barack Obama took time out of his busy schedule to attend our joint signing ceremony today,” commented Tan Sri Mohd Bakke. “We see this investment as symbolic of stronger business ties between the two countries, and the beginning of a long-term partnership with Verdezyne. Sime Darby’s investment will accelerate the development of Verdezyne’s technology and create opportunities to leverage our sustainable palm based materials into higher-value downstream renewable products.”

Photos of the event are available via the Verdezyne media contacts listed below.

About Verdezyne

Verdezyne is an industrial biotechnology company using proven and proprietary metabolic pathway engineering tools to develop unique yeast strains for cost-effective production of bio-based chemicals. Current investors in Verdezyne include BP Alternative Energy Ventures, DSM Venturing B.V., OVP Venture Partners and Monitor Ventures. For more information, visit www.verdezyne.com.

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20140428005876/en/

CONTACT

Verdezyne:
Verdezyne
Aida
Yodites, 760-707-5200
Corporate Communications
ayodites@verdezyne.com
or
Sparkpr
Bill
Douglass, 646-504-0890
bdouglass@sparkpr.com
or
Sime
Darby:

Sime Darby Berhad
Ahmad Shahriman Johari,
(603)2711-0923
Head, External Communications
Group
Communications & Corporate Affairs
shahriman.johari@simedarby.com

同じカテゴリーの記事 

  • Poxel Provides a Financial Update for the First Quarter 2024 and Announces the Postponement of its 2023 Full-Year Results Release
  • ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
  • PROTEINA Initiates Global Clinical Validation Project with Emory University School of Medicine, USA
  • AriBio 获得欧洲药品管理局对AR1001治疗阿尔茨海默病3期临床试验(POLARIS-AD)的授权
  • AriBio Receives EMA Phase 3 Clinical Trial Authorisation for AR1001 in Treatment of Alzheimer’s Disease (POLARIS-AD)